A recent study investigated the rise in cases of immune checkpoint inhibitor (ICI)-mediated myocarditis and myositis among advanced melanoma patients at a single center between 2014 and 2021.
The analysis showed that out of 366 patients treated from 2014 to 2019, there were no cases of myocarditis, whereas from 2019 to 2021, 10 out of 246 patients (4.1%) developed myocarditis, alongside 10 cases of myositis.
The results indicate a notable increase in these serious conditions during the COVID-19 era, suggesting a need for better risk management and treatment guidelines for affected patients.